Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi

Commentary
Video

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

“We got to present the subgroup analysis of the Transcend-NHL-001 mantle cell lymphoma cohort study. This is a study that investigated lisocabtagene maraleucel in patients with relapsed refractory mantle cell lymphoma. And this is actually a post hoc analysis of patients based on number of prior lines of therapy, as well as by response to prior Bruton tyrosine kinase inhibitor.”

Lisocabtagene maraleucel (liso-cel) has demonstrated its ability to yield durable complete responses in patients with heavily pretreated mantle cell lymphoma and was FDA-approved for this indication in May 2024.1 Subgroup analyses of outcomes after liso-cel in these patients according to prior lines of therapy and prior Bruton tyrosine kinase inhibitor treatment were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 31 to June 4, in Chicago, Illinois.2

CGTLive spoke with study coauthor Manali Kamdar, MD, to learn more about the subanalyses and its goal. She went over the different stratified groups, their treatment history, and disease characteristics.

REFERENCES
1. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. News release. FDA. May 30, 2024. Accessed May 30, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma
2. Palomba ML, Siddiqi T, Gordon LI, et al. Lisocabtagenemaraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL). Presented at: 2024 (ASCO) Annual Meeting; May 31 - June 4; Chicago, Illinois. Abstract #7016
Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.